OR WAIT 15 SECS
Medidata has acquired the digital biomarker business of MC10. MC10’s offerings will bring clinical analytics and biosensor capabilities to Medidata’s existing Patient Cloud solutions in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments), and biomarker discovery.
Remote, patient-centered technologies have become an essential part of clinical research, especially in the age of COVID-19; the physical restrictions placed on patients and clinical sites caused by the pandemic can interfere with launching a clinical study and carrying it to completion. Wearable sensors are used in about 15% of studies, and the use of sensors is expected to grow to approximately 70% by 2025.
“Medidata is an exceptional fit for MC10. Our combined expertise will help customers and partners take a more data-driven approach to bringing targeted therapies to patients,” said Ben Schlatka, co-founder and CEO, MC10. “We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients.”
Read the full release, here.